Fate Therapeutics Inc. [NASDAQ: FATE] stock went on an upward path that rose over 1.12% on Friday, amounting to a one-week price increase of more than 1.31%. The company report on October 15, 2020 that Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting.
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that five abstracts for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting being held virtually from November 9-14, 2020.
Accepted abstracts include clinical data from 15 patients in the dose-escalation stage of the Company’s Phase 1 clinical trial of FT500 in advanced solid tumors (NCT03841110), which includes nine patients in Regimen A (three once-weekly doses of FT500 for up to two 30-day cycles as monotherapy) and six patients in Regimen B (three once-weekly doses of FT500 for up to two 30-day cycles in combination with checkpoint inhibitor therapy). The Company is currently enrolling the dose-expansion stage of the Phase 1 clinical trial for patients with non-small cell lung cancer or classical Hodgkin lymphoma who are refractory to, or have relapsed on, checkpoint inhibitor therapy. Each patient in the dose-expansion stage is to receive three once-weekly doses of FT500 at 300 million cells per dose, each with IL-2 cytokine support, for up to two 30-day cycles in combination with the same checkpoint inhibitor on which the patient failed or relapsed.
Over the last 12 months, FATE stock rose by 231.34%. The one-year Fate Therapeutics Inc. stock forecast points to a potential downside of -23.14. The average equity rating for FATE stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $4.18 billion, with 79.31 million shares outstanding and 73.15 million shares in the current float. Compared to the average trading volume of 804.83K shares, FATE stock reached a trading volume of 1608073 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Fate Therapeutics Inc. [FATE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FATE shares is $39.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FATE stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Fate Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 13, 2020. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on March 04, 2020, representing the official price target for Fate Therapeutics Inc. stock. Previously, the target price had yet another raise to $22, while BMO Capital Markets analysts kept a Market Perform rating on FATE stock. On December 30, 2019, analysts increased their price target for FATE shares from 27 to 33.
The Average True Range (ATR) for Fate Therapeutics Inc. is set at 2.27, with the Price to Sales ratio for FATE stock in the period of the last 12 months amounting to 316.45. The Price to Book ratio for the last quarter was 8.13, with the Price to Cash per share for the same quarter was set at 6.21.
FATE Stock Performance Analysis:
Fate Therapeutics Inc. [FATE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.31. With this latest performance, FATE shares gained by 31.78% in over the last four-week period, additionally plugging by 60.00% over the last 6 months – not to mention a rise of 231.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FATE stock in for the last two-week period is set at 68.71, with the RSI for the last a single of trading hit 71.36, and the three-weeks RSI is set at 67.24 for Fate Therapeutics Inc. [FATE]. The present Moving Average for the last 50 days of trading for this stock 37.85, while it was recorded at 48.30 for the last single week of trading, and 31.01 for the last 200 days.
Insight into Fate Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Fate Therapeutics Inc. [FATE] shares currently have an operating margin of -943.14. Fate Therapeutics Inc.’s Net Margin is presently recorded at -919.00.
Return on Total Capital for FATE is now -45.06, given the latest momentum, and Return on Invested Capital for the company is -44.32. Return on Equity for this stock declined to -48.44, with Return on Assets sitting at -38.09. When it comes to the capital structure of this company, Fate Therapeutics Inc. [FATE] has a Total Debt to Total Equity ratio set at 11.00. Additionally, FATE Total Debt to Total Capital is recorded at 9.91, with Total Debt to Total Assets ending up at 8.91. Long-Term Debt to Equity for the company is recorded at 10.31, with the Long-Term Debt to Total Capital now at 9.29.
Reflecting on the efficiency of the workforce at the company, Fate Therapeutics Inc. [FATE] managed to generate an average of -$551,399 per employee. Receivables Turnover for the company is 42.72 with a Total Asset Turnover recorded at a value of 0.04.Fate Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.90 and a Current Ratio set at 11.90.
FATE Stock EPS
With the latest financial reports released by the company, Fate Therapeutics Inc. posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -5.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FATE.
Fate Therapeutics Inc. [FATE] Insider Position Details
There are presently around $4,178 million, or 94.68% of FATE stock, in the hands of institutional investors. The top three institutional holders of FATE stocks are: REDMILE GROUP, LLC with ownership of 12,629,737, which is approximately 12.597% of the company’s market cap and around 0.40% of the total institutional ownership; FMR LLC, holding 6,337,023 shares of the stock with an approximate value of $308.23 million in FATE stocks shares; and BLACKROCK INC., currently with $296.71 million in FATE stock with ownership of nearly 9.217% of the company’s market capitalization.
Positions in Fate Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 126 institutional holders increased their position in Fate Therapeutics Inc. [NASDAQ:FATE] by around 17,080,363 shares. Additionally, 66 investors decreased positions by around 6,872,899 shares, while 22 investors held positions by with 61,953,172 shares. The mentioned changes placed institutional holdings at 85,906,434 shares, according to the latest SEC report filing. FATE stock had 55 new institutional investments in for a total of 5,196,464 shares, while 12 institutional investors sold positions of 424,558 shares during the same period.